Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial.
Féray C, Campion L, Mathurin P, Archambreaud I, Mirabel X, Bronowicki JP, Rio E, Perret C, Mineur L, Oberti F, Touchefeu Y, Gournay J, Regnault H, Edeline J, Rode A, Hillion P, Blanc JF, Khac EN, Azoulay D, Luciani A, Preglisasco AG, Faurel-Paul E, Auble H, Mornex F, Merle P. Féray C, et al. Among authors: campion l. JHEP Rep. 2023 Jan 29;5(4):100689. doi: 10.1016/j.jhepr.2023.100689. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 36937990 Free PMC article.
No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahé MA, Supiot S. Marchand V, et al. Among authors: campion l. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1053-9. doi: 10.1016/j.ijrobp.2009.06.024. Epub 2009 Oct 31. Int J Radiat Oncol Biol Phys. 2010. PMID: 19880259
Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan.
Dubois N, Rio E, Ripoche N, Ferchaud-Roucher V, Gaugler MH, Campion L, Krempf M, Carrie C, Mahé M, Mirabel X, Paris F. Dubois N, et al. Among authors: campion l. Radiother Oncol. 2016 May;119(2):229-35. doi: 10.1016/j.radonc.2016.03.014. Epub 2016 Apr 21. Radiother Oncol. 2016. PMID: 27113798 Free article. Clinical Trial.
Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.
Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, Rio E, Milano GA, Mahier-Ait Oukhatar C, Carrie C. Supiot S, et al. Among authors: campion l. Oncotarget. 2018 Apr 24;9(31):22147-22157. doi: 10.18632/oncotarget.25189. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774129 Free PMC article.
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.
Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J. Bennouna J, et al. Among authors: campion l. Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19. Clin Colorectal Cancer. 2019. PMID: 30415988
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X, De Laroche G, Beckendorf V, Sargos P, Créhange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Campion L, Supiot S. Vaugier L, et al. Among authors: campion l. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1061-1067. doi: 10.1016/j.ijrobp.2018.12.020. Epub 2018 Dec 14. Int J Radiat Oncol Biol Phys. 2019. PMID: 30557672 Free article. Clinical Trial.
191 results